Brain tumor trial aims to find kinder chemo for toddlers

NCT ID NCT07291102

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial compares two standard chemotherapy regimens for children under 5 with a low-risk type of medulloblastoma. The main goal is to see which approach better protects thinking and learning skills 2.5 years after diagnosis. The study will also track survival and side effects. About 96 children will take part across multiple hospitals.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
chemotherapy (carboplatin, etoposide, cisplatin, vincristine, cyclophosphamide, methotrexate, thiotepa)
What this could lead to
If successful, this trial could identify which standard chemotherapy regimen better preserves thinking and learning abilities in young children with medulloblastoma.
What could go wrong
This is an early-stage comparison of existing treatments, not a new therapy. The study is small (96 participants) and results may not apply to all patients. Chemotherapy carries risks like infection, organ damage, and long-term side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MEDULLOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Children's of Alabama

    Birmingham, Alabama, 35233, United States

  • Nationwide Children's Hospital

    Columbus, Ohio, 43205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.